Published in Front Pharmacol on January 31, 2012
A miR-34a-SIRT6 axis in the squamous cell differentiation network. EMBO J (2013) 1.18
Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond) (2012) 1.10
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
Resveratrol increases brown adipose tissue thermogenesis markers by increasing SIRT1 and energy expenditure and decreasing fat accumulation in adipose tissue of mice fed a standard diet. Eur J Nutr (2014) 1.02
Nicotinamide phosphoribosyltransferase in malignancy: a review. Genes Cancer (2013) 0.97
DNA damage and repair in atherosclerosis: current insights and future perspectives. Int J Mol Sci (2012) 0.90
Sirtuin-3 (SIRT3) and the Hallmarks of Cancer. Genes Cancer (2013) 0.88
Targeting Histone Deacetylases in Diseases: Where Are We? Antioxid Redox Signal (2014) 0.88
Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach. Oncotarget (2014) 0.87
The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients (2014) 0.85
Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells. J Cancer Prev (2013) 0.84
Epigenetic drugs: a novel anti-aging strategy? Front Genet (2012) 0.82
Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem (2014) 0.81
Antidicer RNAse activity of monocyte chemotactic protein-induced protein-1 is critical for inducing angiogenesis. Am J Physiol Cell Physiol (2013) 0.80
Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress. Cancer Sci (2014) 0.80
The controversial world of sirtuins. Drug Discov Today Technol (2014) 0.80
Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics (2016) 0.80
Disc cell senescence in intervertebral disc degeneration: Causes and molecular pathways. Cell Cycle (2016) 0.79
Role of sirtuins in stem cell differentiation. Genes Cancer (2013) 0.79
Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. Int J Clin Exp Pathol (2014) 0.79
SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1. Int J Clin Exp Med (2015) 0.78
Post-translational modification of proteins in toxicological research: focus on lysine acylation. Toxicol Res (2013) 0.78
SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells. Med Sci Monit (2016) 0.77
SIRT1 inhibition affects angiogenic properties of human MSCs. Biomed Res Int (2014) 0.77
The role of sirtuins in cellular homeostasis. J Physiol Biochem (2016) 0.77
Kluyveromyces lactis: a suitable yeast model to study cellular defense mechanisms against hypoxia-induced oxidative stress. Oxid Med Cell Longev (2012) 0.76
Acetylation reduces SOX9 nuclear entry and ACAN gene transactivation in human chondrocytes. Aging Cell (2016) 0.76
Alternative splicing regulated by butyrate in bovine epithelial cells. PLoS One (2012) 0.75
Induction of Nuclear Enlargement and Senescence by Sirtuin Inhibitors in Glioblastoma Cells. Immune Netw (2016) 0.75
Advancements in the delivery of epigenetic drugs. Expert Opin Drug Deliv (2015) 0.75
Unraveling the Anticancer Effect of Curcumin and Resveratrol. Nutrients (2016) 0.75
Changes in sirtuin 2 and sirtuin 3 mRNA expressions in rheumatoid arthritis. Eur J Rheumatol (2017) 0.75
Sirtuins in metabolism, DNA repair and cancer. J Exp Clin Cancer Res (2016) 0.75
Phosphorylated SIRT1 associates with replication origins to prevent excess replication initiation and preserve genomic stability. Nucleic Acids Res (2017) 0.75
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. Dig Dis Sci (2017) 0.75
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell (2001) 15.97
Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science (2000) 12.98
Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science (2006) 11.20
Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science (2004) 7.29
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell (2010) 5.40
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Mechanism of human SIRT1 activation by resveratrol. J Biol Chem (2005) 4.86
A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature (2010) 4.39
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol (2006) 3.37
How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer (2008) 3.17
Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab (2005) 3.15
Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol (2004) 3.00
SIRT6 promotes DNA repair under stress by activating PARP1. Science (2011) 2.99
Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res (2006) 2.92
SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci (2009) 2.80
Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem (2001) 2.80
Sirtuin functions in health and disease. Mol Endocrinol (2007) 2.38
The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res (2009) 2.29
Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A (2001) 2.23
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene (2008) 1.78
Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer (2006) 1.73
A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci (2007) 1.65
Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure (2007) 1.53
The dual role of sirtuins in cancer. Genes Cancer (2011) 1.45
Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J Med Chem (2008) 1.31
Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem (2007) 1.19
High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol (2008) 1.18
Sirt7-dependent inhibition of cell growth and proliferation might be instrumental to mediate tissue integrity during aging. J Physiol Pharmacol (2008) 1.15
Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta (2008) 1.09
The conserved role of sirtuins in chromatin regulation. Int J Dev Biol (2009) 1.08
Sirtuin inhibitors. Expert Opin Ther Pat (2009) 1.05
Mammalian Sirt1: insights on its biological functions. Cell Commun Signal (2011) 0.98
Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. Mol Cancer Ther (2011) 0.88
Sirtuins, bioageing, and cancer. J Aging Res (2011) 0.86
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med (2004) 2.72
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell (2010) 2.50
Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell (2013) 2.32
Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov (2007) 1.91
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008) 1.80
"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology (2009) 1.59
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem (2005) 1.51
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep (2009) 1.39
A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol (2004) 1.35
Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med (2004) 1.25
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol (2008) 1.21
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood (2013) 1.19
Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells (2014) 1.19
Trials with 'epigenetic' drugs: an update. Mol Oncol (2012) 1.19
Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res (2005) 1.13
epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem (2008) 1.13
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood (2012) 1.12
Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem (2005) 1.10
Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. Proc Natl Acad Sci U S A (2011) 1.09
Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics (2012) 1.08
Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One (2010) 1.08
Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J Med Chem (2007) 1.08
Rarity of human T helper 17 cells is due to retinoic acid orphan receptor-dependent mechanisms that limit their expansion. Immunity (2012) 1.07
Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res (2008) 1.07
Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol (2004) 1.06
Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia. Blood (2012) 1.02
HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta (2008) 1.02
Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem (2006) 1.02
Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem (2006) 0.98
HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J Mol Endocrinol (2010) 0.98
Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. ChemMedChem (2007) 0.97
Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem (2009) 0.97
Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol Pharmacol (2007) 0.97
Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer Res (2014) 0.96
Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem (2010) 0.96
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J Med Chem (2012) 0.96
Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem Cells Dev (2009) 0.95
Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie (2012) 0.94
Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. Bioorg Med Chem (2011) 0.92
Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors. Mol Cancer Ther (2008) 0.91
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. J Med Chem (2013) 0.91
Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat (2009) 0.90
Cannabinoid receptor 1 influences chromatin remodeling in mouse spermatids by affecting content of transition protein 2 mRNA and histone displacement. Endocrinology (2010) 0.90
Endocannabinoid control of sperm motility: the role of epididymus. Gen Comp Endocrinol (2007) 0.89
Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorg Med Chem Lett (2008) 0.89
Distinct signaling pathways mediate stimulation of cell cycle progression and prevention of apoptotic cell death by estrogen in rat pituitary tumor PR1 cells. Mol Biol Cell (2003) 0.88
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res (2006) 0.88
Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. Mol Cancer Ther (2011) 0.88
New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations. Int J Biochem Cell Biol (2008) 0.87
Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov (2011) 0.87
Identification of tri- and tetracyclic pyrimidinediones as sirtuin inhibitors. ChemMedChem (2010) 0.86
Carbamate prodrug concept for hydroxamate HDAC inhibitors. ChemMedChem (2011) 0.86
A gradient of 2-arachidonoylglycerol regulates mouse epididymal sperm cell start-up. Biol Reprod (2009) 0.86
Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO. Cancer Cell (2009) 0.85
Low 17beta-estradiol levels in CNR1 knock-out mice affect spermatid chromatin remodeling by interfering with chromatin reorganization. Biol Reprod (2013) 0.85
Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities. ChemMedChem (2008) 0.85
Histone deacetylase inhibitors: a patent review (2009 - 2011). Expert Opin Ther Pat (2012) 0.85
Regulation of interleukin-8 gene at a distinct site of its promoter by CCAAT enhancer-binding protein homologous protein in prostaglandin E2-treated human T cells. J Biol Chem (2008) 0.85
Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia. Int J Biochem Cell Biol (2008) 0.84
Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances. Clin Cancer Res (2012) 0.84
Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int J Biochem Cell Biol (2005) 0.84
Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol (2010) 0.84
Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. Int J Biochem Cell Biol (2007) 0.83
Identification of microRNA expression patterns in cutaneous and uveal melanoma cell lines. Tumori (2014) 0.83
HDAC modulation and cell death in the clinic. Exp Cell Res (2012) 0.83
Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J Med Chem (2006) 0.83
1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells. J Med Chem (2014) 0.82
Nuclear size as estrogen-responsive chromatin quality parameter of mouse spermatozoa. Gen Comp Endocrinol (2013) 0.82
Relationship between genome and epigenome--challenges and requirements for future research. BMC Genomics (2014) 0.82
Laccase treatment impairs bisphenol A-induced cancer cell proliferation affecting estrogen receptor alpha-dependent rapid signals. IUBMB Life (2008) 0.82